Form 8-K - Current report:
SEC Accession No. 0001193125-25-005629
Filing Date
2025-01-14
Accepted
2025-01-14 06:16:38
Documents
14
Period of Report
2025-01-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d908944d8k.htm   iXBRL 8-K 23934
2 EX-99.1 d908944dex991.htm EX-99.1 25673
  Complete submission text file 0001193125-25-005629.txt   178873

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nuvl-20250113.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nuvl-20250113_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nuvl-20250113_pre.xml EX-101.PRE 11264
16 EXTRACTED XBRL INSTANCE DOCUMENT d908944d8k_htm.xml XML 3638
Mailing Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 508-446-2272
Nuvalent, Inc. (Filer) CIK: 0001861560 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40671 | Film No.: 25527658
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)